Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 24, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

Classification of Drugs by CNS Access: An Insight from Quantitative Blood-Brain Transport Characteristics
Kiril Lanevskij, Pranas Japertas and Remigijus Didziapetris, Advanced Chemistry Development Inc.

Aim of this study was to identify relationships between quantitative blood-brain transport parameters and qualitative data indicating whether the compound penetrates into the brain efficiently enough to exhibit action in the CNS.

More Information
An In Silico Test Battery for Rapid Evaluation of Genotoxic and Carcinogenic Potential of Chemicals
Kiril Lanevskij, Liutauras Juska, Justas Dapkunas, Andrius Sazonovas, Pranas Japertas and Remigijus Didziapetris, of ACD/Labs and Vilnius University

The FDA guidance for industry states impurities under the ICH threshold may be exaluated for genotoxicity and carcinogenicity. This study uses an expert system to detect mutagens and compounds labeled as potent carcinogens by the FDA.

More Information
A Systematic Review of Lifestyle Modification in Adults with Non-Alcoholic Fatty Liver Disease
C. Thoma, C. P. Day and M. I. Trenell, Newcastle University

This study reviews the causes of non-alcoholic fatty liver disease and the associated risk factor for type 2 diabetes and cardiovascular disease.

More Information
Cytotoxicity Screen of Mangiferin and its Major Metabolite Norathyriol in Human Tumor Cell Lines
Souza, J.R.R., Feitosa, J.P.A., Ricardo, N.M.P.S, Trevisan, M.T.S., Frei, E., Ulrich C.M., Owen, R.W.

Many natural products are available worldwide as potential chemoprotective agents against commonly occurring cancers, for example Mangiferin which has low bioavailability and is thought to be mainly available in the colon.

More Information
Nanoliter Volume Pin Tool Transfers as Measured by a Dual-Dye Absorbance Method
Duong T. Chau; Patrick H. Cleveland, Ph.D.; John Thomas Bradshaw, Ph.D.

Increasing costs of chemical compounds and commonly used solvents has pushed high throughput screening labs towards lower working volumes, specifically in the nanoliter range. The ability to controllably dispense “known” nanoliter aliquots of samples is desired, which can readily be achieved using Pin Tools.

More Information
Why Is My Assay Failing? An Approach to Assay Equipment Optimization
Tanya R. Knaide, John Thomas Bradshaw, Kevin Khovananth, Keith Albert

Assays can produce unexpected or failing results for a multitude of reasons. Variability may be introduced at any point within the assay process.

More Information
Validation of an Automated Cell-Based Bioluminescent TNFa Blocker Bioassay
Brad Larson, Tracy Worzella, Rich Moravec, Neal Cosby, Frank Fan, Teresa Surowy and Peter Banks

TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.

More Information
Modeling Disposition of Sotalol following Intravenous and Oral Administration in Healthy Adult Subjects
S. Ray Chaudhuri, V. Lukacova and W. S. Woltosz

Sotalol is a non specific adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmia. Its absorption, distribution and systemic PK or, collectively, ‘disposition’ was modeled and simulated using GastroPlus™ v7.0. Biopharmaceutical properties were obtained from in silico predictions and in vitro measurements.

More Information
Predicting hERG Potassium Channel Affinity with Artificial Neural Network Ensembles
Adam C. Lee, GrazynaFraczkiewicz, Robert Fraczkiewicz, Robert D. Clark and Walter S. Woltosz

Modeling hERG inhibition has gained significant popularity since 2005, when the FDA recognized the correlation between hERG inhibition and a prolonged QT interval by issuing guidance for the evaluation of new non-antiarrythmic drugs against the hERG channel.Long QT syndrome or LQTS is a risk factor for ventricular tachyarrhythmias and sudden death.

More Information
<< 1 2 3 4 5 6 7 >>
Showing Results 21 - 30 of 111
Scientific News
Microscopic “Walkers” Find Their Way Across Cell Surfaces
Technology could provide a way to deliver probes or drugs to cell structures without outside guidance.
Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.
Getting Metabolism Right
Analysis of 89 models of metabolic processes finds flaws in 44 of them — but suggests corrections.
Persistent Pharmacokinetic Challenges to Pediatric Drug Development
Current knowledge of rational drug dose adjustments is limited, greater effort needs to be made to determine ontogenic factors that influence ADME.
‘Tissue Chip’ to Screen Neurological Toxins
UW-Madison team are developing a faster, more affordable way to screen for neural toxins.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Marijuana Compound May Offer Treatment for AD
Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer’s disease.
New Advances in the Pre-clinical Evaluation of Hepatitis B Therapies
Imperial College London to present first public HBV Data from CN Bio in vitro liver model.
ADME of Antibody-Maytansinoid Conjugates
Continued understanding of the ADME properties of ADCs entering clinical evaluations should provide additional insight into attributes that may be necessary for clinical success.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv